OrbusNeich received 2025 Global Cardiovascular International Collaboration Award Win-Win Collaboration in International Cardiovascular Development

(Hong Kong, May 15, 2025) – OrbusNeich Medical Group Holdings Limited (“OrbusNeich” or the “Group”; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (“PCI”) and percutaneous transluminal angioplasty (“PTA”) procedures, was awarded the “2025 Global Cardiovascular International Collaboration Award” at the “Global Cardiovascular Conference 2025”. This honor fully recognizes the Group’s outstanding contributions to driving innovations in cardiovascular medical technology that improves well-being globally by international collaboration.

Mr. David Chien, Chairman, Executive Director and Chief Executive Officer of OrbusNeich, said, “We are deeply honored that OrbusNeich’s 25 years of dedication to international markets has earned widespread recognition. Our global sales network, spanning over 70 countries and regions, enables us to develop and sell our own innovative and high-quality products that address the unmet clinical needs in various markets. Recently, this global set-up has evolved into a collaborative platform for introducing cutting-edge vascular intervention products from other manufacturers to the international market. This expansion provides medical professionals and patients with a broader range of treatment options. Moving forward, we remain committed to fully leveraging our global platform with a collaborative mindset so as to enhance healthcare accessibility and ultimately accomplish our mission of improving quality of life of patients worldwide.”

The “Global Cardiovascular Awards 2025” is organized by the professional medical device media “MedTech” and its platform “Cardiology Devices”. The “Global Cardiovascular International Collaboration Award” aims to recognize companies that have successfully promoted cardiovascular medical devices to the international market and cooperated with the world’s top institutions to promote technological development. OrbusNeich stood out as one of the winners of this year’s award due to its sales network covering more than 70 countries and regions, its independent research and development and manufacturing capabilities, and its diversified business model of “direct sales + distribution”.

Ms. Jasmine Lu, Director of Regulatory Affairs (China) of OrbusNeich (third right), accepts the “Global Cardiovascular International Collaboration Award” at Global Cardiovascular Conference 2025 on behalf of the Group.

－ End －

About OrbusNeich Medical Group Holdings Limited
OrbusNeich is a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. Headquartered in Hong Kong, China, our Group sells its products in more than 70 countries and regions worldwide. It is also actively expanding into structural heart disease. With an in-house R&D team boasting over 20 years of product development expertise, our Group has developed world-leading proprietary technologies.